Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1545-1552

  Wu, Kaijie ^a   Zeng, Jin ^a   Li, Lei ^a   Fan, Jinhai ^a   Zhang, Dong ^a   Xue, Yan ^a   Zhu, Guodong ^a   Yang, Lin ^a   Wang, Xinyang ^b   He, Dalin ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Epithelial to mesenchymal transition; Nuclear factor B; Prostate cancer; Silibinin; SLUG; ZEB1

Indexed keywords

CYTOKERATIN 18; GELATINASE A; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SILIBININ; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; VIMENTIN; ZEB1 TRANSCRIPTION FACTOR; ANTIOXIDANT; MESSENGER RNA; SILYMARIN;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MESENCHYME CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TRANSPORT; UPREGULATION; CELL ADHESION; CELL LINE; CELL MOTION; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MESODERM; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIOXIDANTS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KERATIN-18; MALE; MATRIX METALLOPROTEINASE 2; MESODERM; NEOPLASM METASTASIS; NF-KAPPA B; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SILYMARIN; TRANSCRIPTION FACTORS; UP-REGULATION; VIMENTIN;

EID: 77951742472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000794     Document Type: Article

References (37)

1. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics. CA Cancer J Clin 44: 7-26, 1994.
2. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007.
3. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2: 442-454, 2002.
4. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
5. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M and Bonavida B: Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 28: 3573-3585, 2009.
6. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.
7. Post-White J, Ladas EJ and Kelly KM: Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 6: 104-109, 2007.
8. Gazák R, Walterová D and Kren V: Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem 14: 315-338, 2007.
9. Agarwal R, Agarwal C, Ichikawa H, Singh RP and Aggarwal BB: Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26: 4457-4498, 2006.
10. Singh RP and Agarwal R: Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 4: 1-11, 2004.
11. Ramasamy K and Agarwal R: Multitargeted therapy of cancer by silymarin. Cancer lett 269: 352-362, 2008.
12. Singh RP and Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45: 436-442, 2006.
13. Mokhtari MJ, Motamed N and Shokrgozar MA: Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol Int 32: 888-892, 2008.
14. Singh RP, Raina K, Sharma G and Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14: 7773-7780, 2008.
15. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
16. Thiry JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
17. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
18. Huber MA, Beug H and Wirth T: Epithelial-mesenchymal transition: NF-κB takes center stage. Cell Cycle 3: 1477-1480, 2004.
19. Min C, Eddy SF, Sherr DH and Sonenshein GE: NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104: 733-744, 2008.
20. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 14: 569-581, 2004.
21. De Craene B, van Roy F and Berx G: Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal 17: 535-547, 2005.
22. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, Kirchner T, Behrens J and Brabletz T: The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68: 537-544, 2008.
23. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and Berx G: SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 33: 6566-6578, 2005.
24. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
25. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007.
26. Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L, Fan JH, Wang XY and He DL: Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin 30: 1162-1168, 2009.
27. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW and Zhau HE: Microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66: 1664-1673, 2006.
28. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC and Chung LW: Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25: 601-610, 2008.
29. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE and Chung LW: Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18: 858-870, 2008.
30. Singh RP, Dhanalakshmi S, Mohan S, Agarwal C and Agarwal R: Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-κB in mouse epidermal JB6 cells. Mol Cancer Ther 5: 1145-1153, 2006.
31. Luo Y, He DL, Ning L, Shen SL, Li L, Li X, Zhau HE and Chung LW: Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 98: 1315-1319, 2006. (Pubitemid 44721249)
32. Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009.
33. Shukla S and Gupta S: Suppression of constitutive and tumor necrosis factor α-induced nuclear factor (NF)-κB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-κB-responsive genes. Clin Cancer Res 10: 3169-3178, 2004.
34. Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R: Silibinin inhibits constitutive and TNFα-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis. Oncogene 21: 1759-1767, 2002. (Pubitemid 34259039)
35. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW and O'Regan RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68: 2479-2488, 2008.
36. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S and Nakshatri H: NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724, 2007.
37. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH and Sonenshein GE: Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, Slug and an invasive phenotype. Cancer Res 67: 11742-11750, 2007.